Last reviewed · How we verify
Ferumoxytol intravenous
At a glance
| Generic name | Ferumoxytol intravenous |
|---|---|
| Also known as | IV iron |
| Sponsor | Auerbach Hematology Oncology Associates P C |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Virtual Histology of the Bladder Wall for Bladder Cancer Staging (EARLY_PHASE1)
- Sucrosomial Vs Intravenous Iron for Preoperative Anemia (PHASE4)
- A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma (PHASE1)
- Early Antenatal Support for Iron Deficiency Anemia (PHASE4)
- Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia (NA)
- Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient (PHASE3)
- Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferumoxytol intravenous CI brief — competitive landscape report
- Ferumoxytol intravenous updates RSS · CI watch RSS
- Auerbach Hematology Oncology Associates P C portfolio CI